Update on Gout: New Therapeutic Strategies and Options

Overview

Journal Nat Rev Rheumatol

Specialty Rheumatology

Date 2010 Jan 5

PMID 20046204

Citations 128

Authors

Robert Terkeltaub

Affiliations

Soon will be listed here.

Abstract

Gout, a disease recognized since antiquity, has increased in prevalence in recent years and the clinical profile of this disease has become increasingly complex, owing to large numbers of cases with iatrogenic factors, multiple comorbidities, advanced age, and hyperuricemia and arthritis refractory to treatment. In this Review, key advances in gout research made during the past decade are summarized. Revised strategies for safe and effective employment of dietary measures and pharmacologic treatments for active gouty arthritis, prevention of gout flares and urate lowering are also reviewed, with an emphasis on dosing of colchicine and allopurinol, and the evidence-based approach to systemic glucocorticosteroid treatment of acute gout. Also discussed are new and emerging treatments for gout and hyperuricemia, and the potential influence of dual energy CT imaging on treatment. In this context, the therapeutic role of febuxostat, and clinical development of pegylated uricase urate-lowering therapy and interleukin 1 antagonism for gouty inflammation are reviewed. Collectively, novel approaches will hopefully lead to improved management of hyperuricemia and gout, and also to improvements in patient-centered outcomes, even for those who have previously failed to respond to treatment.

Citing Articles

A comprehensive analysis of trends in the burden of gout in China and globally from 1990 to 2021.

Xie S, Xiao H, Xu L, Li G, Zhang F, Luo M Sci Rep. 2025; 15(1):3310.

PMID: 39865102 PMC: 11770106. DOI: 10.1038/s41598-025-86090-z.

Data Insights on the Risks of Local Heat and Massage in Gouty Arthritis Treatment.

Mehra S, Mehra K, Mehra N, Kale S, Manchanda B J Orthop Case Rep. 2025; 15(1):260-265.

PMID: 39801867 PMC: 11723740. DOI: 10.13107/jocr.2025.v15.i01.5194.

Transcutaneous auricular vagus nerve stimulation mitigates gouty inflammation by reducing neutrophil infiltration in BALB/c mice.

Shin J, Lee C, Song J Sci Rep. 2024; 14(1):25630.

PMID: 39463429 PMC: 11514149. DOI: 10.1038/s41598-024-77272-2.

Diagnostic values of different musculoskeletal ultrasound signs, serum uric acid, and their combined detection for gouty arthritis.

Wu J, Yan J, Chang J, Li C, Xia B, Liu S Arch Rheumatol. 2024; 39(2):265-273.

PMID: 38933715 PMC: 11196220. DOI: 10.46497/ArchRheumatol.2024.10366.

Well-defined alginate oligosaccharides ameliorate joint pain and inflammation in a mouse model of gouty arthritis.

Yin C, Lyu Q, Dong Z, Liu B, Zhang K, Liu Z Theranostics. 2024; 14(8):3082-3103.

PMID: 38855180 PMC: 11155397. DOI: 10.7150/thno.95611.

References

Harrold L, Andrade S, Briesacher B, Raebel M, Fouayzi H, Yood R . Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009; 11(2):R46. PMC: 2688196. DOI: 10.1186/ar2659. View

Hornung V, Bauernfeind F, Halle A, Samstad E, Kono H, Rock K . Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008; 9(8):847-56. PMC: 2834784. DOI: 10.1038/ni.1631. View

Feig D, Kang D, Johnson R . Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17):1811-21. PMC: 2684330. DOI: 10.1056/NEJMra0800885. View

Woodward O, Kottgen A, Coresh J, Boerwinkle E, Guggino W, Kottgen M . Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009; 106(25):10338-42. PMC: 2700910. DOI: 10.1073/pnas.0901249106. View

Zharikov S, Krotova K, Hu H, Baylis C, Johnson R, Block E . Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol. 2008; 295(5):C1183-90. PMC: 2584985. DOI: 10.1152/ajpcell.00075.2008. View

Becker M, Schumacher H, Benjamin K, Gorevic P, Greenwald M, Fessel J . Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009; 36(5):1041-8. DOI: 10.3899/jrheum.071229. View

Dehghan A, Kottgen A, Yang Q, Hwang S, Kao W, Rivadeneira F . Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008; 372(9654):1953-61. PMC: 2803340. DOI: 10.1016/S0140-6736(08)61343-4. View

Becker M, Schumacher Jr H, Wortmann R, MacDonald P, Eustace D, Palo W . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23):2450-61. DOI: 10.1056/NEJMoa050373. View

Janssens H, Janssen M, van de Lisdonk E, van Riel P, van Weel C . Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008; 371(9627):1854-60. DOI: 10.1016/S0140-6736(08)60799-0. View

10.

Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E . Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998; 57(9):545-9. PMC: 1752740. DOI: 10.1136/ard.57.9.545. View

11.

Bieber J, Terkeltaub R . Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 2004; 50(8):2400-14. DOI: 10.1002/art.20438. View

12.

Choi H, Al-Arfaj A, Eftekhari A, Munk P, Shojania K, Reid G . Dual energy computed tomography in tophaceous gout. Ann Rheum Dis. 2008; 68(10):1609-12. DOI: 10.1136/ard.2008.099713. View

13.

Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K . Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet. 2008; 83(6):744-51. PMC: 2668068. DOI: 10.1016/j.ajhg.2008.11.001. View

14.

Wall G, Koenigsfeld C, Hegge K, Bottenberg M . Adherence to treatment guidelines in two primary care populations with gout. Rheumatol Int. 2009; 30(6):749-53. DOI: 10.1007/s00296-009-1056-7. View

15.

Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P . EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65(10):1312-24. PMC: 1798308. DOI: 10.1136/ard.2006.055269. View

16.

Singh J, Strand V . Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008; 67(9):1310-6. DOI: 10.1136/ard.2007.081604. View

17.

Dalbeth N, Haskard D . Mechanisms of inflammation in gout. Rheumatology (Oxford). 2005; 44(9):1090-6. DOI: 10.1093/rheumatology/keh640. View

18.

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J . Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237-41. DOI: 10.1038/nature04516. View

19.

Perez-Ruiz F, Calabozo M, Pijoan J, Herrero-Beites A, Ruibal A . Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002; 47(4):356-60. DOI: 10.1002/art.10511. View

20.

Sundy J, Hershfield M . Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep. 2007; 9(3):258-64. DOI: 10.1007/s11926-007-0041-y. View